Needham raised the firm’s price target on Gilead (GILD) to $170 from $140 and keeps a Buy rating on the shares. The company reported Q4 earnings with total product sales of $7.9B, up 8% from Q3 and topping estimates, the analyst tells investors in a research note. The topline beat was driven by another strong performance from the HIV franchise, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $171 from $150 at Morgan Stanley
- Invesco QQQ Trust ETF (QQQ) Daily Update, 2/11/2026
- Gilead price target raised to $152 from $145 at Truist
- Underappreciated Earnings Power: Why Strong HIV Momentum and Margin Expansion Support a Buy on Gilead
- Gilead Sciences: HIV Franchise Strength, Yeztugo Ramp, and Solid 2026 Outlook Underpin Buy Rating and Positive Risk‑Reward